Inhibikase Therapeutics, Inc.
IKT
$1.85
-$0.09-4.64%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -109.98% | -16.50% | -6.67% | -11.29% | 9.08% |
| Total Depreciation and Amortization | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5,243.58% | 382.08% | -42.51% | -60.88% | -7.21% |
| Change in Net Operating Assets | -251.94% | 662.42% | -118.27% | 21.98% | 76.05% |
| Cash from Operations | -9.52% | 3.43% | -30.71% | -12.33% | 16.14% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,634.45% | -0.67% | 176.79% | -56.54% | -112.40% |
| Cash from Investing | -1,634.45% | -0.67% | 176.79% | -56.54% | -112.40% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 54,671.70% | -94.34% | 708.25% | 79,420.00% | 400.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 200.00% | 77.92% | -- |
| Cash from Financing | 54,671.70% | -94.39% | 784.01% | 365.75% | -138,200.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2,657.63% | -396.41% | 110.76% | -19.59% | -143.96% |